课题基金 / 基金详情

PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX

PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX
Zenapax 的 I/II 期开放标签药代动力学和安全性研究
批准号：
6118435
负责人：
ROBERT Bruce ETTENGER
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118435
关键词：
acute disease /disorder chronic disease /disorder chronic renal failure clinical research clinical trial phase I dialysis therapy drug screening /evaluation homologous transplantation human subject human therapy evaluation immunosuppressive kidney transplantation pharmacokinetics transplant rejection

项目摘要

项目成果

ROBERT Bruce ETTENGER的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Kidney transplantation is the treatment of choice for end stage renal disease. Advances in the treatment of allograft rejection have increased the survival of both patients and their grafts. Nevertheless acute and chronic rejection both continue to hamper graft survival. At one year, about 80% of grafts survive about half survive to 8 years. Failed grafts require dialysis and retransplantation when possible. Prolongation of graft survival effectively increases the supply of organs relative to demand.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX